Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Myasthenia Gravis Treatment Market Valuation Change Between Now And 2029?

The market for treating myasthenia gravis has extensively expanded in the last few years. The size of this market is projected to increase from $1.55 billion in 2024 to $1.66 billion in 2025, marking a compound annual growth rate (CAGR) of 6.9%. Factors such as cholinesterase inhibitors, thymectomy procedures, immunosuppressive treatments, the advent of plasma exchange, and patient advocacy have all contributed to the growth observed in the historical period.

The market for treating myasthenia gravis is projected to have a robust growth in the coming years. The market is expected to reach a value of $2.25 billion in 2029, growing at a compounded annual growth rate (CAGR) of 7.9%. The considerable growth projected in the forecast period is driven by factors like biologics and monoclonal antibodies, advancements in genetic and precision medicine, the rise in immune modulating therapies, neuroprotection strategies, and the use of biosimilar medications. Noteworthy trends to be observed in the forecast period include the rise of digital therapeutics, cooperation in research efforts, patient-centered approaches, the application of real-world evidence, and a focus on long-term safety monitoring.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

What Growth-Enabling Forces Are Impacting The Myasthenia Gravis Treatment Market?

The escalating occurrence of myasthenia gravis is projected to catalyze the expansion of the myasthenia gravis treatment market. Myasthenia gravis is an autoimmune disorder characterized by weakness and fatigue in the skeletal muscles. The treatment for myasthenia gravis involves comprehensive healthcare services and patient care to fight the condition. Consequently, the increased occurrence of the disease is stimulating growth in the myasthenia gravis treatment market. For instance, data from the National Organization for Rare Disorders, a non-profit organization supporting those with rare diseases, showed in January 2022 that in the US, the prevalence of autoimmune myasthenia gravis was estimated to be 14–40 per 100,000 population. Similarly, an April 2024 report by the American Journal of Managed Care, a peer-reviewed journal, suggested that based on an average of 1,800 annual myasthenia gravis diagnoses, an annual incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years were estimated. Thus, the increasing prevalence of myasthenia gravis is fueling the myasthenia gravis treatment market’s growth.

What Are The Main Segment Classifications In The Myasthenia Gravis Treatment Market?

The myasthenia gravis treatmentmarket covered in this report is segmented –

1) By Treatment: Medication; Surgery; Other Treatments

2) By Medication Type: Cholinesterase Inhibitors; Corticosteroids; Immunosuppressants; Other Medication Types

3) By End-Use: Hospitals; Clinics; Other End-Uses

Subsegments:

1) By Medication: Anticholinesterase Agents; Immunosuppressants; Monoclonal Antibodies; Corticosteroids

2) By Surgery: Thymectomy

3) By Other Treatments: Plasmapheresis; Intravenous Immunoglobulin (IVIg); Supportive Therapies

Which Emerging Trends Are Reshaping The Myasthenia Gravis Treatment Market Landscape?

One notable trend gaining traction in the myasthenia gravis treatment market is the introduction of novel products. Major players in this market are concentrating their efforts on the creation of unique solutions to ensure their continued market dominance. As an example, in October 2023, Belgium’s UCB Pharma was granted approval from the US Food and Drug Administration (FDA) for Zilucoplan, which is designed for the treatment of adults diagnosed with generalized myasthenia gravis (gMG) and who have tested positive for anti-acetylcholine receptor (AChR) antibodies. This authorization brings forth a new approach to gMG management, known for muscle weakness brought on by an autoimmune response. ZILBRYSQ is distinctive due to its self-administered, daily subcutaneous complement C5 inhibitor. This presents a user-friendly alternative to traditional intravenous therapies that have been the norm in treating gMG.

Which Firms Are Driving Innovation Within The Myasthenia Gravis Treatment Market?

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

What Are The Emerging Regional Trends Driving The Myasthenia Gravis Treatment Market?

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=11980&type=smp

Browse Through More Reports Similar to the Global Myasthenia Gravis Treatment Market 2025, By The Business Research Company

Large Suvs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/large-suvs-global-market-report

Printer Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/printer-global-market-report

Printing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/printing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model